Allogene Teases April Interim Data in 220-Patient ALPHA3 Trial with 25–30% MRD Goal
Allogene plans an April interim futility analysis of its 220-patient ALPHA3 frontline large B-cell lymphoma trial, seeking a 25–30% MRD clearance improvement with cema-cel versus observation. The company estimates a 34,000-patient MRD-positive market and $5B TAM, aiming for peak sales above $2B via expanded allogeneic CAR-T capacity.
1. ALPHA3 Frontline Consolidation Study
The ALPHA3 trial is randomizing approximately 220 MRD-positive large B-cell lymphoma patients 1:1 to receive cema-cel versus observation following six R-CHOP cycles. The primary endpoint is event-free survival, with key secondaries including PFS, OS and MRD clearance; an interim futility analysis targeting a 25–30% absolute MRD clearance improvement is scheduled for April.
2. Manufacturing Scale and Market Outlook
Allogene projects its controlled facilities could produce 20,000–60,000 allogeneic CAR-T doses annually at $10,000–$20,000 cost per dose. Management estimates a 34,000-patient MRD-positive or insufficiently treated population across the U.S. and Europe, a $5 billion TAM and potential peak sales above $2 billion, with enrollment expected to finish by end-2027 and site expansion into Asia-Pacific.
3. ALLO-329 Dual CD19/CD70 Autoimmune Program
ALLO-329 employs dual-target CD19/CD70 CAR-T cells with reduced or no lymphodepletion to treat autoimmune rheumatology indications like SLE, myositis and scleroderma. The dose-escalation RESOLUTION study starts at 20 million cells, testing Cytoxan-only and no lymphodepletion regimens, with initial proof-of-concept readouts expected in June 2026.